Valuation: Cardiol Therapeutics Inc.

Market Cap 196M 139M 122M 114M 105M 13.29B 199M 1.35B 528M 6.59B 522M 511M 22.77B P/E 2026 *
-3.54x
P/E 2027 * -7.31x
Enterprise Value 181M 128M 113M 105M 96.53M 12.27B 184M 1.25B 487M 6.08B 482M 472M 21.02B EV / Sales 2026 *
-
EV / Sales 2027 * 55.9x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
May. 11 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 07 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
May. 07 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
May. 07 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
May. 07 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
Apr. 28 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
Apr. 28 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
Apr. 01 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
Apr. 01 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
Apr. 01 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
Mar. 31 Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Feb. 10 Cardiol Therapeutics Inc. Announces the Publication of Results from Its Phase II Archer Study in ESC Heart Failure CI
Jan. 23 Cardiol Therapeutics Inc. announced that it has received CAD 13.500001 million in funding CI
1 day+3.66%
1 week-3.95%
Current month+14.09%
1 month+12.58%
3 months-8.60%
6 months+27.82%
Current year+29.77%
1 week 1.58
Extreme 1.575
1.85
1 month 1.37
Extreme 1.37
1.85
Current year 1.22
Extreme 1.225
2.33
1 year 1.22
Extreme 1.225
2.33
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.19
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 2017-01-18
Director of Finance/CFO - 2018-08-15
Chief Operating Officer - 2020-12-02
Director TitleAgeSince
Director/Board Member - 2017-12-14
Director/Board Member - 2017-01-18
Chairman - 2021-07-06
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Option

Director

30,000 0.0260%
6/30/26 Option

Chairman

45,238 0.0392%
6/30/26 Option

Director

30,000 0.0260%
Change 5-day change 1-year change 3-year change Capi.($)
+3.66%-3.95%-19.05%+18.88% 139M
0.00%+4.74%-3.17%+11.20% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
-1.81%-4.42%+1.44%+7.80% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.86%+3.78%+48.19%+93.80% 25.24B
Weighted average by Cap. +2.14%+5.03%+72.58%+124.98%

Financials

2026 *2027 *
Net sales - 3.32M 2.36M 2.07M 1.93M 1.77M 225M 3.38M 22.85M 8.94M 112M 8.85M 8.66M 386M
Net income -35.21M -24.99M -21.93M -20.42M -18.78M -2.39B -35.81M -242M -94.83M -1.18B -93.81M -91.78M -4.09B -30.57M -21.7M -19.04M -17.73M -16.31M -2.07B -31.1M -210M -82.34M -1.03B -81.46M -79.7M -3.55B
Net Debt -15.01M -10.65M -9.35M -8.7M -8.01M -1.02B -15.26M -103M -40.42M -505M -39.98M -39.12M -1.74B -10.26M -7.28M -6.39M -5.95M -5.47M -695M -10.43M -70.56M -27.62M -345M -27.32M -26.73M -1.19B
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
26-07-28 CA$1.700 +3.66% 165,965
26-07-27 CA$1.640 -1.80% 111,361
26-07-24 CA$1.670 -4.02% 91,929
26-07-23 CA$1.740 -4.40% 105,070
26-07-22 CA$1.820 +2.82% 110,142
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.700CAD
Average target price
6.000CAD
Spread / Average Target
+252.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRDL Stock